Silexion Therapeutics Corp (SLXN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SLXN SEC filings page.
Silexion Therapeutics Corp (SLXN) reported $155K in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Silexion remains a development-stage business: research spending dwarfs revenue, while operations rely on financing rather than customer receipts.
In FY2025, R&D was$7.1M against revenue of$155K , showing development spending remains disconnected from commercial scale. The near match between free cash flow and operating cash flow indicates that cash use is primarily operating investment rather than heavy physical expansion.
Revenue rebounded from
FY2025 financing provided
Financial Health Signals
Silexion Therapeutics Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Silexion Therapeutics Corp scores -15.17, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.4M) relative to total liabilities ($4.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Silexion Therapeutics Corp passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 3 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Silexion Therapeutics Corp reported a net loss of $11.9M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Silexion Therapeutics Corp reported an operating loss of $11.6M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Silexion Therapeutics Corp generated $14K in revenue in Q2 2026. This represents a decrease of 68.2% from the same quarter a year earlier. Against the prior quarter it is down 56.3%.
Silexion Therapeutics Corp's EBITDA was -$3.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 61.2% from the same quarter a year earlier. Against the prior quarter it is down 33.9%.
Silexion Therapeutics Corp reported -$3.6M in net income in Q2 2026. This represents a decrease of 41.9% from the same quarter a year earlier. Against the prior quarter it is down 29.9%.
Silexion Therapeutics Corp earned $5.17 per diluted share (EPS) in Q2 2026. This represents a decrease of 88.0% from the same quarter a year earlier. Against the prior quarter it is down 38.9%.
Cash & Balance Sheet
Silexion Therapeutics Corp recorded an outflow of $2.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 16.6% from the same quarter a year earlier. Against the prior quarter it is up 19.8%.
Silexion Therapeutics Corp held $2.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Silexion Therapeutics Corp's ROE was -8070.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 5984.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7131.3 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Silexion Therapeutics Corp invested $2.2M in research and development in Q2 2026. This represents an increase of 117.3% from the same quarter a year earlier. Against the prior quarter it is up 61.5%.
Silexion Therapeutics Corp reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
SLXN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-K | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-K | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14K-68.2% | $32K+1500.0% | $70K | $39K | $44K+633.3% | $2K-89.5% | N/A | $0 |
| R&D Expenses | $2.2M+117.3% | $1.4M+132.2% | $3.4M | $2.2M-32.9% | $1.0M+32.9% | $590K-38.6% | N/A | $3.2M+501.3% |
| SG&A Expenses | $1.5M+16.0% | $1.4M+30.1% | $1.0M | $1.1M-76.4% | $1.3M+104.5% | $1.1M+266.8% | N/A | $4.8M+2358.7% |
| Operating Income | -$3.7M-61.1% | -$2.7M-66.6% | -$4.4M | -$3.3M+59.0% | -$2.3M-64.9% | -$1.6M-32.0% | N/A | -$8.0M-999.3% |
| EBITDA | -$3.7M-61.2% | -$2.7M-66.9% | -$4.4M | -$3.3M+59.0% | -$2.3M-65.5% | -$1.6M-32.5% | N/A | -$8.0M-1011.5% |
| Interest Expense | $0 | $0-100.0% | $2K | $0 | $0 | $11K | N/A | $0 |
| Income Tax | N/A | N/A | N/A | $0-100.0% | $3K+50.0% | N/A | N/A | $2K-66.7% |
| Net Income | -$3.6M-41.9% | -$2.7M-57.5% | -$4.4M | -$3.3M+72.5% | -$2.5M-68.1% | -$1.7M-21.9% | N/A | -$11.9M-1366.0% |
| EPS (Basic) | $5.17-88.0% | $8.46-78.0% | -$1.40+99.6% | $2.88-98.9% | $43.19-78.2% | $38.39+212.4% | -$359.91-977.2% | $274.25+35060.3% |
| EPS (Diluted) | $5.17-88.0% | $8.46-78.0% | -$1.40 | $2.88 | $43.19-78.2% | $38.39+212.4% | -$359.91 | $274.25+35060.3% |
| Diluted Shares (Avg) | 687,353+1086.1% | 323,038+614.7% | N/A | 1M | 57,952+678.7% | 45,198-59.5% | N/A | 43,213-95.7% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
SLXN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-K | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-K | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.2M-26.8% | $4.6M-44.6% | $7.2M+152.0% | $11.6M+276.2% | $5.8M+150.4% | $8.3M+131.7% | $2.9M-45.5% | $3.1M |
| Current Assets | $3.7M-28.6% | $4.1M-47.4% | $6.6M+195.0% | $11.1M+262.8% | $5.2M+126.2% | $7.7M | $2.3M-54.8% | $3.0M |
| Cash & Equivalents | $2.2M-35.7% | $2.4M-60.8% | $6.0M+404.7% | $9.2M+368.5% | $3.5M+104.2% | $6.2M+117.3% | $1.2M-74.2% | $2.0M-66.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.2M-26.0% | $4.3M-24.7% | $4.6M-32.7% | $4.6M-39.5% | $5.7M-72.4% | $5.7M+189.7% | $6.9M-66.9% | $7.7M |
| Current Liabilities | $4.0M+84.9% | $4.1M+69.5% | $2.8M-21.7% | $2.8M-22.2% | $2.1M-9.1% | $2.4M | $3.5M+60.4% | $3.6M |
| Non-Current Liabilities | $226K-93.6% | $251K-92.5% | $1.9M-44.3% | $1.9M-54.7% | $3.5M+43987.5% | $3.3M | $3.3M+5542.4% | $4.1M |
| Total Equity | $44K-63.3% | $291K-88.7% | $2.6M+165.3% | $7.0M+252.4% | $120K+100.7% | $2.6M+60.6% | -$4.0M+74.2% | -$4.6M+1.5% |
| Retained Earnings | -$61.5M-29.4% | -$57.9M-28.7% | -$55.2M-27.5% | -$50.8M-22.1% | -$47.5M-60.1% | -$45.0M | -$43.3M-61.3% | -$41.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
SLXN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-K | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-K | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M-16.7% | -$3.6M-48.6% | -$3.0M-3.1% | -$2.8M-7.2% | -$2.5M-135.4% | -$2.5M-40.0% | -$2.9M-132.8% | -$2.7M-287.3% |
| Depreciation & Amortization | $3K0.0% | $2K-50.0% | $3K+125.0% | $4K-81.8% | $3K-57.1% | $4K-50.0% | -$12K-300.0% | $22K+120.0% |
| Stock-Based Compensation | $197K+432.4% | $345K+1542.9% | N/A | $38K-99.3% | $37K+15.6% | $21K-34.4% | N/A | $5.8M+18018.8% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $2K | $0-100.0% | $1K | $6K0.0% | $0-100.0% | $16K+166.7% |
| Free Cash Flow | -$2.9M-16.6% | -$3.6M-48.3% | -$3.0M-3.1% | -$2.8M-6.5% | -$2.5M-135.5% | -$2.5M-39.9% | -$2.9M-132.0% | -$2.7M-286.3% |
| Investing Cash Flow | -$1K0.0% | $0+100.0% | -$7K | $0+100.0% | -$1K | -$6K0.0% | $0+100.0% | -$16K-122.2% |
| Financing Cash Flow | $2.7M+1505.1% | $83K-98.9% | -$221K-110.1% | $8.6M+195.3% | -$195K | $7.4M | $2.2M | $2.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SLXN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-K | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-K | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -26285.7% | -8590.6% | -6294.3% | -8441.0% | -5190.9% | -82500.0% | N/A | N/A |
| Net Margin | -25364.3% | -8540.6% | -6302.9% | -8364.1% | -5688.6% | -86750.0% | N/A | N/A |
| Return on Equity | -8070.4%-5984.6pp | -939.2%-872.1pp | -169.5% | -46.8% | -2085.8% | -67.1%+21.3pp | N/A | N/A |
| Return on Assets | -83.6%-40.5pp | -59.4%-38.5pp | -61.2% | -28.1%+356.1pp | -43.2%+21.1pp | -20.9%+18.8pp | N/A | -384.2% |
| Current Ratio | 0.94-1.5x | 1.00-2.2x | 2.41+1.8x | 3.97+3.1x | 2.44+1.5x | 3.22 | 0.64-1.6x | 0.85 |
| Debt-to-Equity | 95.50+48.2x | 14.81+12.6x | 1.77 | 0.66 | 47.31 | 2.21+1.0x | N/A | N/A |
| Asset Turnover | 0.000.0x | 0.010.0x | 0.01 | 0.000.0x | 0.010.0x | 0.000.0x | N/A | 0.00 |
| FCF Margin | -20892.9% | -11393.8% | -4311.4% | -7289.7% | -5700.0% | -122950.0% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Silexion Therapeutics Corp SLXN | FY2025 | $155K | -$11.9M | N/A | $1.4M | — |
| Galecto, Inc. GLTO | FY2025 | N/A | -$209.8M | N/A | $1.7B | — |
| Qualigen Therapeutics, Inc. QLGN | FY2025 | N/A | -$17.0M | N/A | $6.5M | — |
| Dermata Therapeutics, Inc. DRMA | FY2025 | N/A | -$7.6M | N/A | $5.5M | — |
| Entero Therapeutics, Inc. ENTO | FY2025 | $36K | -$6.4M | N/A | $10.1M | — |
Where Silexion Therapeutics Corp Ranks
Frequently Asked Questions
What is Silexion Therapeutics Corp's annual revenue?
Silexion Therapeutics Corp (SLXN) reported $155K in total revenue for fiscal year 2025. This represents a 453.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Silexion Therapeutics Corp's revenue growing?
Silexion Therapeutics Corp (SLXN) revenue grew by 453.6% year-over-year, from $28K to $155K in fiscal year 2025.
Is Silexion Therapeutics Corp profitable?
No, Silexion Therapeutics Corp (SLXN) reported a net income of -$11.9M in fiscal year 2025.
What is Silexion Therapeutics Corp's EBITDA?
Silexion Therapeutics Corp (SLXN) had EBITDA of -$11.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Silexion Therapeutics Corp's return on equity (ROE)?
Silexion Therapeutics Corp (SLXN) has a return on equity of -457.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Silexion Therapeutics Corp's free cash flow?
Silexion Therapeutics Corp (SLXN) recorded an outflow of $10.8M in free cash flow during fiscal year 2025. This represents a -28.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Silexion Therapeutics Corp's operating cash flow?
Silexion Therapeutics Corp (SLXN) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Silexion Therapeutics Corp's total assets?
Silexion Therapeutics Corp (SLXN) had $7.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Silexion Therapeutics Corp's capital expenditures?
Silexion Therapeutics Corp (SLXN) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Silexion Therapeutics Corp spend on research and development?
Silexion Therapeutics Corp (SLXN) invested $7.1M in research and development during fiscal year 2025.
What is Silexion Therapeutics Corp's current ratio?
Silexion Therapeutics Corp (SLXN) had a current ratio of 2.41 as of fiscal year 2025, which is generally considered healthy.
What is Silexion Therapeutics Corp's debt-to-equity ratio?
Silexion Therapeutics Corp (SLXN) had a debt-to-equity ratio of 1.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Silexion Therapeutics Corp's return on assets (ROA)?
Silexion Therapeutics Corp (SLXN) had a return on assets of -165.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Silexion Therapeutics Corp's P/E ratio?
Silexion Therapeutics Corp (SLXN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.4M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Silexion Therapeutics Corp's price-to-sales ratio?
Silexion Therapeutics Corp (SLXN) trades at 9.3x sales, its market capitalization divided by revenue of $155K revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.4M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Silexion Therapeutics Corp's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Silexion Therapeutics Corp (SLXN) held $6.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.8M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Silexion Therapeutics Corp's Altman Z-Score?
Silexion Therapeutics Corp (SLXN) has an Altman Z-Score of -15.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Silexion Therapeutics Corp's Piotroski F-Score?
Silexion Therapeutics Corp (SLXN) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Silexion Therapeutics Corp's earnings high quality?
Silexion Therapeutics Corp (SLXN) reported a net loss of $11.9M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Silexion Therapeutics Corp cover its interest payments?
Silexion Therapeutics Corp (SLXN) reported an operating loss of $11.6M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.